| __timestamp | Regeneron Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 2614539000 | 580006000 |
| Thursday, January 1, 2015 | 3711019000 | 676585000 |
| Friday, January 1, 2016 | 4560733000 | 778966000 |
| Sunday, January 1, 2017 | 5475166000 | 671251000 |
| Monday, January 1, 2018 | 6276700000 | 463508000 |
| Tuesday, January 1, 2019 | 7081200000 | 445724000 |
| Wednesday, January 1, 2020 | 7377200000 | 399725000 |
| Friday, January 1, 2021 | 13634200000 | 296656000 |
| Saturday, January 1, 2022 | 10612500000 | 293122000 |
| Sunday, January 1, 2023 | 11301400000 | 268323000 |
| Monday, January 1, 2024 | 12231500000 | 304979000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Regeneron Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. from 2014 to 2023. Regeneron, a leader in biotechnology, has shown a remarkable growth trajectory, with its gross profit increasing by over 330% from 2014 to 2023. In contrast, Taro, a key player in generic pharmaceuticals, experienced a decline of approximately 54% over the same period. Notably, Regeneron's gross profit peaked in 2021, while Taro's highest point was in 2016. The data highlights the contrasting fortunes of these companies, reflecting broader industry trends and strategic decisions. As we look to the future, the missing data for Regeneron in 2024 leaves room for speculation on its continued growth.
Gross Profit Analysis: Comparing Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.
Johnson & Johnson vs Taro Pharmaceutical Industries Ltd.: A Gross Profit Performance Breakdown
Gross Profit Comparison: Sanofi and Taro Pharmaceutical Industries Ltd. Trends
Bristol-Myers Squibb Company and Regeneron Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis
Key Insights on Gross Profit: Bristol-Myers Squibb Company vs Taro Pharmaceutical Industries Ltd.
Gross Profit Trends Compared: Regeneron Pharmaceuticals, Inc. vs HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Gross Profit Comparison: Genmab A/S and Taro Pharmaceutical Industries Ltd. Trends
Gross Profit Analysis: Comparing Viatris Inc. and Taro Pharmaceutical Industries Ltd.
Pharming Group N.V. vs Taro Pharmaceutical Industries Ltd.: A Gross Profit Performance Breakdown
Gross Profit Analysis: Comparing Taro Pharmaceutical Industries Ltd. and MiMedx Group, Inc.